StockNews.com initiated coverage on shares of bluebird bio (NASDAQ:BLUE – Free Report) in a research note released on Thursday. The firm issued a sell rating on the biotechnology company’s stock.
Several other equities analysts also recently commented on BLUE. JPMorgan Chase & Co. downgraded bluebird bio from an “overweight” rating to a “neutral” rating in a report on Thursday, August 15th. Cantor Fitzgerald reissued a “neutral” rating on shares of bluebird bio in a research report on Monday, September 16th. Wells Fargo & Company lowered their price target on bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Wednesday, September 25th. Bank of America dropped their price objective on bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. Finally, Robert W. Baird decreased their target price on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, bluebird bio presently has a consensus rating of “Hold” and an average price target of $4.63.
Read Our Latest Stock Report on BLUE
bluebird bio Stock Up 1.7 %
NASDAQ:BLUE traded up $0.01 during trading hours on Thursday, reaching $0.49. The company’s stock had a trading volume of 3,169,897 shares, compared to its average volume of 7,664,248. bluebird bio has a one year low of $0.45 and a one year high of $5.53. The business’s 50-day moving average is $0.60 and its 200-day moving average is $0.88. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.68 and a quick ratio of 0.57. The company has a market cap of $53.57 million, a price-to-earnings ratio of -0.65 and a beta of 0.75.
bluebird bio (NASDAQ:BLUE – Get Free Report) last released its quarterly earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. bluebird bio had a negative return on equity of 207.25% and a negative net margin of 567.29%. The company had revenue of $18.57 million for the quarter. Equities research analysts predict that bluebird bio will post -1.42 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Sequoia Financial Advisors LLC increased its holdings in bluebird bio by 48.0% in the 1st quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 13,000 shares during the period. Allegheny Financial Group LTD acquired a new stake in shares of bluebird bio during the 2nd quarter valued at about $25,000. Price T Rowe Associates Inc. MD increased its stake in bluebird bio by 113.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock valued at $71,000 after acquiring an additional 29,113 shares during the period. Bayesian Capital Management LP bought a new stake in bluebird bio in the first quarter valued at about $52,000. Finally, American International Group Inc. raised its position in bluebird bio by 77.4% in the first quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 41,177 shares in the last quarter. 87.43% of the stock is currently owned by institutional investors and hedge funds.
bluebird bio Company Profile
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Featured Articles
- Five stocks we like better than bluebird bio
- Compound Interest and Why It Matters When Investing
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- How to Invest in Biotech Stocks
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- How to Effectively Use the MarketBeat Ratings Screener
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Should you invest $1,000 in bluebird bio right now?
Before you consider bluebird bio, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and bluebird bio wasn’t on the list.
While bluebird bio currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
